November 1st, 2017
View Archives Issues
Postsurgical opioid prescriptions often lead to extra pills stored in unsecured locations in homes. This represents a potential source for non-medical opioid use and associated morbidity and mortality for patients and their families.
New data from the Women’s Health Initiative may be reassuring for women on postmenopausal hormone therapy. The data show no higher mortality rate with hormone use after long-term follow-up.
Romosozumab appears to outperform alendronate for fracture prevention in women with osteoporosis, but an increase in cardiovascular adverse events has derailed FDA approval.
In this section: The FDA unveils new adverse events dashboard tool, announces intent to hasten generic drug approvals, greenlights a generic drug to treat multiple sclerosis, greenlights biosimilar to treat multiple types of cancers, gives go ahead to leukemia treatment, and approves updated herpes zoster vaccine.